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TLRGiven the self nature of cancer, anti-tumor immune response is weak. As such, acute inﬂamma-
tion induced by microbial products can induce signals that result in initiation of an inﬂamma-
tory cascade that helps activation of immune cells. We aimed to compare the nature and
magnitude of acute inﬂammation induced by toll-like receptor ligands (TLRLs) on the tumor
growth and the associated inﬂammatory immune responses. To induce acute inﬂammation in
tumor-bearing host, CD1 mice were inoculated with intraperitoneal (i.p.) injection of Ehrlich
ascites carcinoma (EAC) (5 · 105 cells/mouse), and then treated with i.p. injection on day 1,
day 7 or days 1 + 7 with: (1) polyinosinic:polycytidylic (poly(I:C)) (TLR3L); (2) Poly-ICLC
(clinical grade of TLR3L); (3) Bacillus Calmette Guerin (BCG) (coding for TLR9L); (4) Com-
plete Freund’s adjuvant (CFA) (coding for TLR9L); and (5) Incomplete Freund’s Adjuvant
(IFA). Treatment with poly(I:C), Poly-ICLC, BCG, CFA, or IFA induced anti-tumor activities
as measured by 79.1%, 75.94%, 73.94%, 71.88% and 47.75% decreases, respectively in the total
number of tumor cells collected 7 days after tumor challenge. Among the tested TLRLs, both
poly(I:C) (TLR3L) and BCG (contain TLR9L) showed the highest anti-tumor effects as
reﬂected by the decrease in the number of EAc cells. These effects were associated with a 2-
fold increase in the numbers of inﬂammatory cells expressing the myeloid markers CD11b+-
Ly6G+, CD11b+Ly6G, and CD11b+Ly6G. We concluded that Provision of the proper
inﬂammatory signal with optimally deﬁned magnitude and duration during tumor growth
can induce inﬂammatory immune cells with potent anti-tumor responses without vaccination.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Cairo University.
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For many years, treatment of cancer was primarily focused on
surgery, chemotherapy and radiation, but as researchers learn
more about how the body ﬁghts cancer on its own, antitumour
immunotherapies have been developed. With this regard,
recent preclinical and clinical studies have been focusing on
designing antitumor treatment strategies based on induction
of speciﬁc anti-tumor immune responses [1]. Unfortunately,
however, these immunotherapeutic approaches have not
reached the optimal efﬁciency against tumor [2]. In addition,
they require the identiﬁcation of certain tumor antigens and
tumor-reactive T cells, which are not available in many of
cancer settings. As such, immunotherapeutic approaches that
depend on induction of non-speciﬁc immune responses could
be advantageous to the approaches since they do not need
requirements. Therefore, exploring and developing non speciﬁc
immunotherapies is of paramount signiﬁcance in the clinical
application of cancer therapy.
One approach for non speciﬁc immunotherapy could be by
the induction of inﬂammation in particular acute inﬂammation
with agents that code for danger signals [3]. Microbial prod-
ucts, which bind to toll like receptors (TLRLs) on immune
cells in general and innate immune cells in particular, are the
optimal candidate to induce acute inﬂammation since they
code for danger signals that are known to activate immune
cells [4]. TLRL are a class of transmembrane signaling proteins
that play a critical role in the innate and adaptive immune
response against invading pathogen by recognizing various
protein, carbohydrates, lipids, and nucleic acids of invading
microorganisms [5]. They are expressed by different types of
leukocytes or other cell types [6,7]. TLRL expression proﬁles
differ among tissues and cell types. TLRL are predominantly
expressed on antigen-presenting cells (APCs), such as macro-
phages or dendritic cells, and their signaling activates APCs
to provoke innate immunity and as a consequence adaptive
immunity [8,9]. TLRL are mainly located on the plasma
membrane with the exception of TLR3, TLR7 and TLR9
which are localized in the endoplasmic reticulum (ER) [8–10].
Mammalian TLRL include a large family consisting of ten
to thirteen different types of toll-like receptors named simply
TLR1 to TLR13. To date, ten human and thirteen murine
TLR have been identiﬁed, TLR1–TLR9 are conserved between
the human and mice [11]. However, there are TLRL found in
humans and not present in all mammals, for example, TLR10
in humans is present in mice [12]. It has been found that each
TLR has been shown to recognize speciﬁc microbial component
and that TLR have common effects, including inﬂammatory
cytokine or up-regulation of co-stimulatory molecule expres-
sion, but also have their speciﬁc function such as production
of IFN-b [13]. TLR are substances that bind to and activate
TLR. The latter constituent in different types of organisms at
the cell surface or at the internal cell compartments.
The most common TLRLs that have been used in induction
of potent acute inﬂammation is poly(I:C) which is a synthetic
double-stranded RNA that mimics virus and binds to TLR3
[5]. Poly-ICLC (Hiltinol) is a clinical grade of poly(I:C)
which is a synthetic, nuclease-resistant, hydrophilic complex
of poly(I:C) and stabilized with poly-L-lysine and
carboxymethyl cellulose [14]. BCG is an inﬂammatory signal
to macrophage, lymphocytes, granulocytes, and dendritic cells[15]. It contains cytidine phosphate guanosine (CpG) which is
known to bind to TLR9 [16]. BCG can be used alone or
integrated into IFA to form CFA.
EAC cells increased via rapid cell division during the prolif-
erating phase and in the load peritoneal cavity. Ascites ﬂuid
accumulation occurred in parallelism with the proliferation
of tumor cells [17].
In this study, we aimed to determine the impact of the nat-
ure, magnitude, and timing of different inﬂammatory stimuli
on the host anti-tumor activity. Our hypothesis is that provi-
sion of the proper inﬂammatory signal with optimally deﬁned
magnitude and duration during cancer growth can induce
inﬂammatory cells with potent anti-tumor responses leading
to signiﬁcant decreases in tumor growth even in the absence
of vaccination.Material and methods
Mice
All experiments were carried out on adult female Swiss albino
mice 20 g and aged between 8 and 16 weeks. The mice were pur-
chased from Theodore Bilharz Research Institute, Giza, Egypt.
Mice were acclimatized at least two weeks before experimenta-
tion and randomly divided into the experimental groups, ten
or twelve mice for each. Mice were maintained at regular light
and dark cycles, and provided with standard food and water
ad libitum. This work was conducted based on the guidelines for
the use of experimental animals in research at Department of
Zoology, Faculty of Science, Tanta University, Egypt.
Tumor cells
All experiments in this study were performed using the breast
tumor cell line Ehrlich ascites carcinoma (EAC). EAC is a
transplantable, poorly differentiated malignant tumor which
appeared originally as a spontaneous breast carcinoma in a
mouse. It grows in both solid and ascitic forms [18]. The parent
cell line was purchased from The National Cancer Institute,
Cairo University, Egypt. The tumor cell line was maintained
by serial intraperitoneal (i.p.) transplantation of 2.5 · l06
viable tumor cells in 0.3 ml of saline into female swiss albino
mice (8–10 weeks old).
Reagents
Polyinosinic-polycytidylic acid (poly(I:C)), purchased from
Sigma Chem. Co., (St. Louis, Mo., USA), was stored at 4 C
in dark until use. Poly(I:C) was dissolved in saline (0. 9%).
Poly-ICLC is kindly gifted by Dr. Salazar Andres (Oncovir,
Washington, DC, USA). All reagents were obtained in suspen-
sion form and stored at 2–8 C. Poly-ICLC was diluted in sal-
ine (0.9%). Complete Freund’s adjuvant (CFA) was purchased
from Sigma to Aldrich, USA. Incomplete Freund’s Adjuvant
(IFA) was purchased from Sigma Aldrich, USA. Bacillus
Calmette Guerin (Immune BCG-T) was purchased from the
vacsera company, Giza, Egypt. It is a suspension of a live
attenuated mycobacterium Bacillus calmette Guerin is a
stabilizing medium. For injection each vial containing
90 mg/3 ml was suspended in 50 ml (0.9%) saline.
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Seven days after i.p. implantation of 0.5 · 106 EAC, 3 or 4
mice were killed and EAC cells were collected from the
peritoneal cavity, washed for at least twice with 30 ml PBS
by centrifugation for 10 min at 1200 rpm, 40C. After making
an appropriate dilution, the total number of tumor cells was
determined with trypan blue exclusion test. Harvested cells
were diluted with saline (0.9%) to the required concentration
(usually 0.5 · 106 cells/ml PBS) used in each experiment, and
then 100lL containing 0.5 · 106 EAC cells were implanted
through i.p. injection into the mouse of the experimental
groups and treated with PBS or inﬂammatory stimuli. On
day 1 or day 15 post EAC injection, mice were i.p. treated
with PBS, a single injection of (100 lg/mouse in 200 ll)
BCG (1 · 106 c.f.u), the other groups were treated with
(100 lg/mouse in 200 ll) poly(I:C), (50 lg/mouse in 200 ll)
Poly-ICLC, (100 lg/mouse in 100 ll) CFA, (100 ll/mouse)
IFA.Assessment of EAC proliferation
Seven days or ﬁfteen days after i.p implantation (0.5 · 106)
mice were sacriﬁced and (EAC) cells were collected. Tumor
cells were grown slowly from day 1 to 7 post cell inoculation
and then aggressively after day 7 onward. When the mice were
sacriﬁced on day 7 the tumor cells were grow aggressively
onward. To insure that all tumor cells were harvested the
peritoneal cavity was washed twice by 5 ml PBS and all cells
were pooled. Cells were washed for at least twice. After
making an appropriate dilution, the total number of tumor
cells was determined with trypan blue exclusion assay.
Harvested cells were diluted with saline (0.9%) to the required
concentration used in each experiment and counted with
hemocytometer.Flow cytometry
At the indicated time points, mice were bled from the orbital
sinus to harvest peripheral blood and then sacriﬁced to harvest
the spleen and tumor cells. Erythrocytes were then depleted
with ACK buffer (Invitrogen, Carlsbad, CA) [19]. Spleen cell
suspensions were prepared and counted using a hemocytome-
ter with trypan blue dye exclusion as described previously
[20,21]. Table 1 showed different subsets of myeloid cells.
Cells were stained with mAbs against CD11b (FITC anti-
CD11b), Ly6G (APC anti-Ly6G) for 20 min in dark at room
temperature. The cells were then washed twice with PBS and
then acquired using Partec ﬂow cytometer and analyzed using
ﬂow Jo software (BD Biosciences).Table 1 Different subset of myeloid cells.
Myeloid cells subset Description
CD11b+Ly6G+ Immature neutrophil
CD11b+Ly6G Macrophage in case of spleen and
monocytes in case of peripheral blood
CD11bLy6G+ Mature neutrophilStatistical analysis
Statistical analyses were performed using Student’s t-test [22].
GraphPad Prism (GraphPad Software, Inc., San Diego, CA)
was used to analyze the mouse survival data. P values less than
0.05 were considered signiﬁcant. Data were represented as
mean ± SD.
Results
Comparing the anti-tumor effects of the inﬂammatory signals on
tumor growth
We compared the effect of the TLR3L agonists poly(I:C) and
Poly IC-LC as well as BCG and CFA which contain TLR9L
agonists on the anti-tumor response against EAC cells. In
addition, we used IFA which is similar to CFA except that it
does not contain BCG. All of these agents were injected on
days 1 and 15 post EAC challenges. Treatment with these
inﬂammatory stimuli induced decreases in the numbers of
EAC harvested from the peritoneal cavity as compared with
control tumor-bearing mice (Fig. 1A), where Poly-ICLC,
BCG, CFA, poly(I:C) and IFA induced 79.1%, 75.49%,
73.94%, 71.88% and 47.75%, respectively (Fig. 1B). Similar
results were obtained when these agents were injected on days
1 + 7 and the analysis was done on day 8 post EAC challenge
(data not shown).
Comparing the immunomodulatory effects of the inﬂammatory
signals on myeloid cells inﬁltrate in EAC ascites
To understand whether the anti-tumor effect shown in Fig. 1
was associated with effect on immune cell we analyzed the num-
ber of myeloid cells in tumor site. Inﬁltration of myeloid cells
into tumor has been shown to be critical in mediation in the
anti-tumor immune response [23]. As such, we analyzed the
number of cells expressing the myeloid receptors Ly6G and
CD11b in the tumor. Mice were challenged with EAC and then
treated with the inﬂammatory stimuli on both days 1 and 7.
Analysis of the expression of CD11b Ly6G in these mice (day
8) after treatment showed that each inﬂammatory stimulus
induced a different effect. As shown in Fig. 2A, BCG resulted
in a signiﬁcant increase in the percentage of CD11b+Ly6G+ (2-
fold) when compared with tumor bearing mice. In contrast,
IFA induced decrease (2-fold) in percentage of these cells.
Treatment with BCG or IFA did not induce any changes on
the percentage of either CD11b+ or Ly6G+ single positive
cells. While poly(I:C) did mot induce a marked change in the
percentage of CD11b+Ly6G+, it induced 1.5-fold increases
in CD11b+ Ly6G or Ly6G+ CD11b, respectively.
Treatment with Poly-ICLC or CFA induced a 2-fold decrease
in percentage of CD11b+Ly6G+ and 5- and 3-fold decreases
in CD11b+ Ly6G and Ly6G+ CD11b, respectively
Fig. 2B and C.
Impact of the timing of administration of the inﬂammatory
signals on their anti-tumor effects
Since poly(I:C) and BCG showed similar effects and they are
coding different TLRLs (Figs. 1 and 2), these microbial
A
B
* * * * 
* 
* 
Fig. 1 The anti-tumor effects of the inﬂammatory signals on tumor growth. (A) Shows the total number of EAC cells harvested in each
group. (B) Shows the percentage of EAC cells. *P value 60.01 as compared to control.
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CD11b 
A
B
IFACFABCGPoly IC-LCPoly(I:C)PBSMyeloid cells
1.211.1182.735.724.58CD11b +Ly6G +
2.891.132.821.592.183.27CD11b -Ly6G +
3.041.764.441.813.445.58 CD11b +Ly6G -
C
Poly IC-LC IFA BCG CFA 
Fig. 2 Effects of the inﬂammatory signals on myeloid cells inﬁltrate in EAC ascites. (A) Shows a representative control in tumor. (B)
Shows the number of cell expressing myeloid (Ly6G+ CD11b+) or (Ly6G+ CD11b) or (Ly6G CD11b+) were estimated after staining
with anti-Ly6G and anti-CD11b using ﬂow cytometry. (C) Table shows the percentage of myeloid cells in quadrates.
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timing of their administration is critical to their anti-tumor
effects. To address this issue, EAC-bearing mice were treated
with poly(I:C) or BCG either on day 1 or 7 or both and then
the mice were sacriﬁced on day 8 to count EAC number. As
shown in (Fig. 3B), when poly(I:C) was administrated both
on days 1 + 7 or on day 1 it induced 63.01% and 61.24%
decreases in the numbers of EAC (Fig. 3A). However, it
induced 33.7% when administrated on day 7 only. When
BCG was administrated on days 1 + 7 or on day 1, it induced
decrease in the number of EAC by 84.02% and 68.63%,
respectively. Interestingly, however, when BCG was
administrated only on day 7 it did not induce any change in
the numbers of EAC. Taken together, these results indicatethat the timing of injection of the inﬂammatory signals is crit-
ical for induction of their anti-tumor effect since injection of
BCG in day 1 but not in day 7 increases antitumor effect.
Comparing the impact of the timing of the inﬂammatory signals
on the frequency of myeloid cells
Mice were injected with tumor on d0, and treated on day 1 or 7
or both days 1 + 7 with either poly(I:C) (100 lg) or BCG
(500 lg). Mice were bled 4 h after each injection of poly(I:C)
and BCG and then all mice were sacriﬁced on day 8 to analyze
the numbers of Ly6G+ and CD11b+ expressed cells in blood,
spleen and tumor. Analysis of the frequency of cells expressing
Ly6G and CD11b in the tumor site showed that
A B
*
*
*
*
Fig. 3 Impact of the timing of administration of the inﬂammatory signals on their anti-tumor effects, (A) shows the total number of
EAC cells harvested in each group and (B) shows the percentage of EAC cells. *P value 60.01 as compared to control.
Acute inﬂammation induces immunomodulatory effects on myeloid cells 247administration of BCG on day 1 + 7 or day 7 resulted in
signiﬁcant increase in the percentage of CD11b+Ly6G+ by
30- and 6-fold, respectively and also 11- and 1.8-fold, respec-
tively, of Ly6GCD11b+ but induced increase of 1.5-fold
when administered on day 1 only (Fig. 4A and B). Its
administration on days 1 + 7, but not on either of these days
alone, resulted in a 4, 5-fold increase in percentage of
Ly6G+CD11b cells (Fig. 4C).
Poly(I:C) administration on days 1 + 7 induced 3-fold
increase in the numbers of CD11b+Ly6G+ cells and 7-fold
increase in their numbers when administered either on day 1
or 7 (Fig. 4A). Interestingly, however, administration of
poly(I:C) on day 1 or 7 or both days 1 and 7 induced 2, 7.3Fig. 4 Effects of the timing of the inﬂammatory signals on myeloid c
(Ly6G+ CD11b+) was estimated after staining with anti-Ly6G and
expressing myeloid (Ly6G CD11b+) was estimated after staining wit
number of cell expressing myeloid (Ly6G+ CD11b) was estimated afand 12-fold increases, respectively, in the numbers of
Ly6GCD11b+ cells (Fig. 4B). Further, its administration on
day 1 or days 1 + 7, but not on day 7 alone, induced 2, 2.5-
fold increase in the numbers of Ly6G+CD11b cells (Fig. 4C).
In spleen, BCG, but not poly(I:C), induced a 16-fold
decrease in percentage of CD11b+Ly6G+ cells and a 4-fold
decrease in the number of Ly6GCD11b+ cells. In contrast,
however, poly(I:C), but not BCG, induced a 2-fold increase
in the numbers of Ly6G+CD11b (Fig. 5B) as compared with
the control group PBS (Fig. 5A).
Administrated of BCG, but not poly(I:C), on days 1 + 7
induced 2-fold decrease in numbers of CD11b+Ly6G+.
Although administration of BCG or poly(I:C) on days 1 + 7ells in tumor site. (A) Shows the number of cell expressing myeloid
anti-CD11b using ﬂow cytometry. (B) Shows the number of cell
h anti-Ly6G and anti-CD11b using ﬂow cytometry. (C) Shows the
ter staining with anti-Ly6G and anti-CD11b using ﬂow cytometry.
PBS Poly(I:C) day1 Poly(I:C) day7 Poly(I:C) day1 +day7 
BCG day1 BCG day7 BCG day1+day7 
Ly
6G
 
CD11b 
A B
BCG 
Day1+7
BCG 
Day 7
BCG
Day 1
Poly(I:C) 
day1+7
Poly(I:C)
Day7 
Poly(I:C)
Day 1
PBSMyeloid cells
2.110.8640.2474.574.785.964.04CD11b+Ly6G+
2.374.933.334.135.924.092.06CD11b-Ly6G+
2.861.121.391.481.534.334.82 CD11b+Ly6G-
C
Fig. 5 Effects of inﬂammation on myeloid cells in spleen. (A) Shows representative control. (B) Shows analysis of the number of
expressing cells of myeloid (Ly6G+ CD11b+) or (Ly6G+ CD11b) or (Ly6G CD11b+) were estimated after staining with anti-Ly6G
and anti-CD11b using ﬂow cytometry. (C) Table shows the percentage of myeloid cells in quadrates.
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Ly6GCD11b+ cells, only poly(I:C) induced 2-fold increase
in the number of Ly6G+CD11b cells. Administration of
BCG, but not poly(I:C), on day 7 induced 4-fold decrease in
number of CD11b+Ly6G+. However, BCG and poly(I:C)
induced 4-fold and 3-fold decreases, respectively, in the num-
bers of Ly6GCD11b+ cells and 2-fold increase in the number
of Ly6G+CD11b cells (Fig. 5B).
Analyses of the frequency of cells expressing Ly6G and
CD11b in the blood showed that administration of poly(I:C)
or BCG on day 1 had no effect on the number of
CD11b+Ly6G+ but induced 25 and 16-fold decreases, respec-
tively, in the numbers of Ly6G+CD11b (Fig. 6A and C).
While poly(I:C) induced 2-fold increase in the numbers of
Ly6GCD11b+ cells, BCG induced 3.5-fold increase
(Fig. 6C) as compared with control group PBS.
Administrated of poly(I:C) on days 1 + 7 induced 2-fold
increase in the number of CD11b+Ly6G+ while it induced
3.2 and 10-fold decreases in the numbers of Ly6GCD11b+
and Ly6G+CD11b cells, respectively (Fig. 6A–C). Its admin-
istration on day 7 only induced 1.8-fold and 7-fold increases in
numbers of CD11b+Ly6G+ and Ly6G+CD11b cells but with
no effect on Ly6GCD11b+ cells.
Administration of BCG on days 1 + 7 induced a 2-fold
increase in the numbers of Ly6G+CD11b cells while it induced
5 and 2.5-fold decreases in the numbers of Ly6GCD11b+ and
Ly6GCD11b+, respectively (Fig. 6A–C). Its administration
on day 7 induced 1.7-fold increase in the numbers of
CD11b+Ly6G+ cells and 10-fold decrease in the numbers of
Ly6G-CD11b+ cells butwith no effect onLy6GCD11b+ cells.Comparing the anti-tumor effects of inﬂammation on tumor
growth according to magnitude
To further evaluate whether the antitumor effects of poly(I:C)
and BCG depend on their magnitude, they were injected at dif-
ferent doses. They were injected on days 1 + 7 post tumor
injection since they showed the optimal effects when they were
injected at these 2 time points. Mice were sacriﬁced on day 8.
Consistent with the data in Fig. 1, administration of these two
agents at the doses used in the legend of Fig. 1 (100 lg)
induced decreases in the numbers of EAC harvested from
the peritoneal cavity as compared with control tumor-
bearing mice (Fig. 7A). Unexpectedly, however, injection of
poly(I:C) at higher (200 lg) dose induced only 69.14% anti-
tumor effect as compared with its effect at 100 lg (89.93%),
and its effects disappeared when injected at 50 lg. In contrast
to poly(I:C), however, injection of BCG at 1000, 500, and
100 lg induced 89.89%, 76.86% and 81.9% decrease, respec-
tively, in the numbers of EAC as compared to untreated mice
(Fig. 7B). Taken together, these results indicate that the dose
of TLR is critical for induction of their anti-tumor effect.Comparing the impact of magnitude of inﬂammation on the
numbers of myeloid cells
Administration of 100, 500 and 1000 lg BCG induced 29, 9,
and 11-fold increases, respectively, in numbers of
CD11b+Ly6G+ cells in the tumor site (Fig. 8A). Injection
of BCG at 500 lg induced 3-fold increase in percentage of
Fig. 6 Effects of inﬂammation on myeloid cells in blood. (A) Shows the number of cell expressing myeloid (Ly6G+ CD11b+) was
estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry. (B) Shows the number of cell expressing myeloid (Ly6G
CD11b+) was estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry. (C) Shows the number of cell expressing
myeloid (Ly6G+ CD11b) was estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry.
A
B
 ** *
* *
*
*
*
*
Fig. 7 The anti-tumor effects on tumor growth according to magnitude. (A) Shows the total number of EAC cells harvested in each
group. (B) Shows the percentage of EAC cells. *P value 60.01 as compared to control.
Acute inﬂammation induces immunomodulatory effects on myeloid cells 249Ly6GCD11b+ and induced a 2-fold increase in the numbers
of Ly6G+CD11b cells (Fig. 8B and C). Its injection at 100
or 1000 lg induced 5 or 90-fold increase in the numbers of
Ly6G+CD11b cells, respectively but with no effect on
Ly6GCD11b+ cells in the tumor site.
Administration of poly(I:C) at 50 or 100 or 200 lg had no
effect on the numbers of CD11b+Ly6G+ cells as compared
with untreated EAC bearing mice (Fig. 8A). poly(I:C) at
100 lg, but not at 50 or 200 lg, however, resulted in 3.5-fold
decrease and 9-fold increase in the number of
Ly6GCD11b+ and Ly6GCD11b+ cells, respectively, in
the tumor site (Fig. 8B and C).
In case of spleen as shown in Fig. 9, we found that
BCG(1000 lg) and BCG(100 lg) induced increase of 1.5, 2.5-
fold but BCG(500 lg) induced increase (3.5-fold) in percentageof CD11b+Ly6G+ however all induced decrease (3.8, 6.3 and
2.7-fold) respectively in CD11b+Ly6G. In contrast, all
induced increase (12.3, 11.3 and 18-fold) respectively in
Ly6G+CD11b.
Administration of poly(I:C) at 200 lg, but not at 100 lg,
induced 1.5-fold increase in the number of CD11b+Ly6G+
cells, while it induced 2-fold decrease in their number when
injected at 50 lg. Treatment with poly(I:C) at 50, 100 and
200 lg induced 3.5-, 1.5 and 2-fold decreases, respectively, in
the numbers of Ly6GCD11b+ cells and induced 3-, 2 and
2-fold increases, respectively, in the numbers of
Ly6G+CD11b cells (Fig. 9).
Fig. 10A shows the numbers of CD11b+ and Ly6G+ cells
analyzed in the blood 4 h after administration of poly(I:C) or
BCG after 4 h of 1st injection on day 1 of tumor challenge.
A
B
*
** *
*
*
* *
C
Fig. 8 Effects of inﬂammation on myeloid cells in tumor bearing mice. (A) Shows the number of cell expressing myeloid (Ly6G+
CD11b+) was estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry. (B) Shows the number of cell expressing
myeloid (Ly6G CD11b+) was estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry. (C) Shows the number of
cell expressing myeloid (Ly6G+ CD11b) was estimated after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry.
PBS 
BCG 500 BCG 100 BCG 1000 Poly(I:C) 100 Poly(I:c) 200 Poly(I:C) 50 
Ly6G 
CD
11
b 
A
B
C Poly(I:C)
200
Poly(I:C)
100
Poly(I:C)
50
BCG 1000BCG
500
BCG
100
PBSMyeloid cells
8.934.592.963.8017.813.35.46CD11b+Ly6G+
1.941.562.3711.316.710,30.909CD11b-Ly6G+
4.245.762.532.283.151.738.76 CD11b+Ly6G-
Fig. 9 Effects of inﬂammation on myeloid cells In spleen. (A) Shows representative control. (B) Shows in the analysis of the number of
expressing cells of myeloid (Ly6G+ CD11b+) or (Ly6G+ CD11b) or (Ly6G CD11b+), were estimated after staining with anti-Ly6G
and anti-CD11b using ﬂow cytometry. (C) Table shows the percentage of myeloid cells in quadrates.
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induced 1.5-fold decrease in the number of CD11b+Ly6G+
cells in the blood. At 100 lg, but not at 500 or 1000 lg,
BCG induced 2.5-fold increase in the numbers of
Ly6GCD11b+ cells. In contrast, however, injection of BCG
at 100, 500, and 1000 lg induced 4, 5, and 3-fold decreases,respectively, in the numbers of Ly6G+CD11b cells in the
blood as compared with control group (Fig. 10C).
Treatment with 200 lg poly(I:C) resulted in 1.5-fold
increase in the number of CD11b+Ly6G+ cells as compared
to untreated EAC bearing mice. In contrast, however, its
administration at 50 or 100 lg induced 1.5-fold decrease in
A Poly(I:C) 200 BCG 100 BCG 500 BCG 1000 Poly(I:C) 100 Poly(I:C) 50 
PBS 
CD
11
b 
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100
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BCG 1000BCG
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40.125.520.235.52318.631.5CD11b+Ly6G+
1.711.560.8821.671.732.57 1.17CD11b-Ly6G+
3.498.293.77 4.892.863.5615.6 CD11b+Ly6G-
Poly(I:C)
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100
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4.2514.46.89 7.569.674.5415.6 CD11b+Ly6G-
D
Fig. 10 Effects of inﬂammation on myeloid cells in blood. The number of cells expressing myeloid (Ly6G+ CD11b+) or (Ly6G+
CD11b) or (Ly6G CD11b+) after staining with anti-Ly6G and anti-CD11b using ﬂow cytometry in blood were analyzed after 4 h of the
1st (A) and the 2nd (B) injection of poly(I:C) and BCG, (C) shows a representative data for control blood, (D) table is shown the
percentage of myeloid cells in quadrates.
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100 or 200 lg/mouse poly(I:C) on day 1 had no effects on
CD11b+Ly6G cells, administration of 50 lg/mouse
poly(I:C) induced 4-fold decrease in the number of these cells.
In contrast, treatment with poly(I:C) at 50, 100, and 200 lg
induced 4.5, 2 and 4-fold decreases, respectively, in the num-
bers of Ly6G+CD11b cells.
Interestingly, in Fig. 10B we found that BCG at 100 or 500
or 1000 lg/mouse was analyzed in the blood 4 h after 2nd
injection in day 7 induced increase (2.5, 3 and 3-fold), respec-
tively in percentage of CD11b+Ly6G+ when. Also BCG at
1000 and 100 lg/mouse induced increase (1.5-fold) in
CD11b+ Ly6G while 500 lg did not induce any changes.
BCG at 100 or 500 or 1000 lg/mouse induced decrease (8, 14
and 7-fold) in percentage of CD11b+Ly6G, respectively.
Treatment with poly(I:C) at 50, 100, and 200 lg induced 2,
2 and 2.5-fold increases, respectively, in the numbers of
CD11b+Ly6G+ cells when compared with tumor bearing
mice. In case of Ly6GCD11b+ cells, however, only treatment
with 200 lg, but not at 50 or 100 lg, poly(I:C) induced 3-fold
increase in their numbers in the blood. In case of
Ly6G+CD11b cells, however treatment with poly(I:C) at
50, 100, and 200 lg induced 14, 14.5 and 7-fold decreases,
respectively, in their numbers in the blood (Fig. 10C).Discussion
In this study we aimed to determine the impact of the nature,
magnitude, and timing of different inﬂammatory stimuli by
its agonists poly(I:C) and Poly-ICLC (TLR3) BCG and CFA
(which are known to code the TLR9 agonist CpG) on the host
anti-tumor activity and the associated response of the immune
cells. Administration of these immune stimuli during the tumor
progression associated with anti-tumor effects which were
dependent on both the magnitude and the timing of induction
of the acute inﬂammation during tumor growth. These antitu-
mor effects also associated with alteration in the numbers of the
myeloid cells with CD11b+Ly6G+ (immature neutrophils),
CD11bLy6G+ (mature neutrophils) and CD11b+Ly6G
(macrophage in case of spleen and monocytes in case of periph-
eral blood) phenotypes. Our results indicate that provision of
the proper inﬂammatory signal with optimally deﬁned magni-
tude and duration during cancer growth can induce inﬂamma-
tory cells with potent anti-tumor responses leading to
signiﬁcant decreases in tumor growth. The results obtained
from this study would led to a simple and effective anti-
tumor treatment using the available inﬂammatory agents even
in the absence of vaccination and chemotherapy.
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induced similar at anti-tumor effects while IFA showed the
lowest effect, indicating that the inﬂammatory stimuli which
code for a TLR ligand are more effective to induce anti-
tumor effects than those without danger signals. The nature
of the TLR ligand seems not important since BCG and CFA
which code for TLR9 showed similar anti-tumor effects to
those of poly(I:C) and polyIC-LC which code for TLR3
ligand. These data also suggest that it is possible to induce
anti-tumor effects in the absence of antigen-speciﬁc
immunotherapy if the proper non-speciﬁc inﬂammatory stim-
uli exist during tumor progression. Taken our results together
with those in the literature, it can be suggested that the addi-
tion of particular inﬂammatory stimuli during immunotherapy
will signiﬁcantly enhance the resultant anti-tumor immunity.
In line with this hypothesis, we and others have recently
reported that the addition of the TLR3 agonist poly(I:C)
and other TLR agonists during vaccination against melanoma
markedly enhanced the resultant anti-tumor CD8 + T cell
responses in terms of the quantity and quality of immune
responses [24,25]. In these studies the adjuvant effects of
TLRLs were tested in lymphodepleted hosts and with or
without adoptive T cell therapy [26]. The studies in which
lymphodepletion was applied suggest that combinatorial
treatments with chemotherapy/immunotherapy and ACT can
markedly improve memory T cell responses [27].
Accordingly, our results indicate that combination of these
inﬂammatory stimuli brieﬂy after anti-cancer chemotherapy
can optimally augment the resultant anti-tumor responses even
in the absence of vaccination.
Although we did not analyze the exact mechanism underly-
ing anti-tumor effects of these TLR ligands against EAC, the
antitumor effects of the tested inﬂammatory stimuli could be
explained by their stimulatory effects on the non speciﬁc com-
ponents of immune system such as macrophag, neutrophils
and NK cells. With this regard, we found that poly(I:C)
increased the number of neutrophils (Ly6G+) by 1.5-fold and
macrophage (CD11b+) by 8-fold. Since the BCG and CFA
did not markedly affect these two populations, it could be sug-
gested that the anti-tumor effects of these stimuli are dependent
on other cells such as NK and DCs. Recent studies also showed
that triggering of TLR signaling pathways induces pro-
inﬂammatory mediators, including cytokines, chemokines,
which in turn induces maturation of DCs [28]. These mediators
in combination with matured DCs activate cytotoxic T lympho-
cytes (CTLs) and NK cells, promoting adaptive immunity [15].
Even though we tested the antitumor effects of TLRLs
using a non transgenic tumor mouse model and in the absence
of vaccination or chemotherapy, the resultant anti-tumor
effects could be mediated by antigen-speciﬁc T cell response.
We challenged the mice with EAC tumor and then treated
them with the TLRLs.
Recent studies including ours showed that myeloid derived
suppressive cells (MDSC) with the phenotype
Ly6G+CD11b+ expand under the effect of tumor and infection
and result in suppression of immune response [29,30].
Interestingly, we found that poly(I:C), polyIC-LC, BCG and
CFA induce increases in the number of the cells with this pheno-
type at tumor site. Recent studies showed that mouse-derived
liver MDSC, but not other myeloid cells CD11b+ Gr1,
suppressed T cell proliferation in allogenic MLR in a dose-
dependent manner [31], indicating that the presence of properinﬂammatory stimuli might interfere with the suppressive func-
tion of these cells or induce their activation. Since poly(I:C) and
BCG increased the number of these cells, it can be suggested that
their adjuvant effects bypassed the suppressive effects of these
cells or they induced their maturation or activation.
Currently, we are testing these two hypotheses. Alternatively,
these cells are not MDSC but mature neutrophils. Studies in
our laboratory are ongoing to address this hypothesis.
As shown in Fig. 3, treatment with BCG on day 1 post
EAC challenge induced 68.1% reduction in the tumor growth
while it had no effect when it was injected on day 7 but
retained or even high (84%) anti-tumor effects when injected
on days 1 + 7. In contrast, when poly(I:C) was injected on
day 1 or day 7 or both, it induced signiﬁcant anti-tumor effects
than when injected only on day 1. These results indicate that
BCG need to be injected early during tumor growth but
poly(I:C) can be still effective even if administrated at later
time points after tumor progression. Although the reason
behind the difference between the anti-tumor effects of these
two danger signals is not clear, it might be related to the fact
that poly(I:C) is speciﬁc for TLR3 and BCG contains other
TLR ligand other than CpG.
Besides the importance of the timing of the administration
of the TLR agonist, our results also indicate the importance of
their magnitude. With this regard, we found that increasing the
timing of these stimuli had higher effect on the number of
CD11b+Ly6G+ while it decreased the numbers of CD11b+
and Ly6G+ in the blood and spleen. Interestingly, poly(I:C)
and BCG induced different patterns on the numbers of these
myeloid cells in the tumor site as compared to circulation, indi-
cating that inﬂammatory stimuli might impact the trafﬁcking
of these cells.
The anti-tumor effects of the tested TLR ligands against
EAC could be attributed to the direct effects on the tumor cells
since recent studies showed that triggering of TLR3 signaling
pathway in cancer cells can decrease their proliferation by
blocking progression through the cell cycle [32,33]. This would
explain in recent studies the clinical interest of TLR3 as indica-
tor of tumor aggressiveness and as a prognostic indicator in
gastric cancer [34].
Conclusions
In sum, our results clearly indicate that provision of certain
inﬂammatory stimuli early or late during tumor progression
can effectively induce tumor regression even in the absence of
vaccination. This effect is probably mediated by the inﬂamma-
tory cells such as myeloid cells. Ultimately, our results would
open further studies in which we can combine these inﬂamma-
tory signals with both conventional chemotherapy and
immunotherapy such as dendritic cells pulsed with tumor lysate.
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